Overview

Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare the pharmacokinetic (PK) profiles of Albuterol Spiromax® and ProAir HFA after administration of a single inhaled dose of 180 mcg albuterol base from each product.

Phase:

Phase 1

Details

Lead Sponsor:

Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries

Treatments:

Albuterol
Procaterol